Research and Markets: Boehringer Ingelheim GmbH: PharmaVitae Profile

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of the "Boehringer Ingelheim GmbH: PharmaVitae Profile" company profile to their offering.

This analysis examines the historical and forecast performance for Boehringer Ingelheim in the Rx pharmaceutical sector. The profile encompasses company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Key reasons to purchase this title

  • Benchmark Boehringer Ingelheim's performance against key rivals in the prescription pharmaceutical sector
  • Evaluate the impact of upcoming patent expiries for Flomax and Sifrol on the company's outlook
  • Track the progress of key new launches including Pradaxa and Ondero, upon which the company is highly reliant

Key Topics Covered:

Chapter 1 About this profile

Chapter structure

Chapter 2 Executive summary

Chapter 3 Quarterly news update

Chapter 4 Company introduction

Chapter 5 Company sales

Chapter 6 Company financials

Chapter 7 Key products and competitors

Chapter 8 Appendix

Companies Mentioned:

  • Abbott Laboratories
  • Astellas Pharma
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo, Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • IMS Health
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc

For more information visit

Source: Datamonitor


Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   Europe  Germany

INDUSTRY KEYWORDS:   Health  Pharmaceutical



Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.